Navigation Links
Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management

KING OF PRUSSIA, Pa., Feb. 21, 2012 /PRNewswire/ -- Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL Behring's Key Issues Dialogue – "Albumin in Clinical Fluid Management."

(Logo: )

The participants engaged in a frank and provocative exchange about the uses and effectiveness of albumin, which is manufactured from human plasma. Albumin is used to stabilize blood pressure in shock or sepsis patients who may be albumin-deficient. It is also used to treat burn patients and augment fluid replacement therapy in cardiac surgery and in certain liver disorders. The participants discussed other patient benefits of albumin, which is a natural human protein.

Mortality rate reduction

"Albumin reduced the odds of post-paracentesis circulatory dysfunction by 61 percent (in one study)," said Mauro Bernardi, M.D., University of Bologna. "Moreover, for the first time, we were also able to show that albumin reduced mortality rate by 36 percent. We do not have a crystalloid plasma expander that reduces mortality as albumin does." Dr. Bernardi said the reduction in mortality rate in this complication of liver disease is based on a meta-analysis performed by his group at the University.

Education gap

"There is a real need to educate healthcare providers about albumin because its use has changed over time," said Gary R. Haynes, M.D., Ph.D., Saint Louis University School of Medicine, when he addressed some of the current perceptions of albumin. "Even some of the literature for volume resuscitation isn't up-to-date because we have better ways of assessing intravascular volume."

Cost of albumin

The cost of albumin versus crystalloids was also considered. Luciano Gattinoni, M.D., University of Milan, framed the cost issue in this way: "Good medicine means good economy, not vice versa. When physicians are pressed to save money, the potential for complications and adverse events increases."

This Dialogue is the most recent in CSL Behring's ongoing series that analyzes critical issues around human plasma-derived and recombinant coagulation factor therapies for patients, caregivers and healthcare providers.

Garrett E. Bergman, M.D., CSL Behring's Senior Director, Medical Affairs North America, said the Dialogue provided important insights. "Because of our varied disciplines, we've achieved a cross-pollination of ideas that is truly unique," Dr. Bergman said. "As Dr. Bernardi observed during the Dialogue, the fact that we can discuss our respective problems and find so many common points of interest is unusual. It's not often that a pathologist and an intensivist have the opportunity to sit down and exchange ideas and experiences."

About CSL Behring

CSL Behring, a leader in the plasma protein therapeutics industry, has provided the international community with albumin for over 50 years. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit or view CSL Limited's Corporate Responsibility Report.

Chris Florentz
Manager, Corporate Communications

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FasterCures Spotlights Addario Lung Cancer Medical Institutes Innovative Research Programs
2. Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System
3. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
4. The butterfly effect in nanotech medical diagnostics
5. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
6. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
7. Rap music powers rhythmic action of medical sensor
8. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
9. Survey: Small Medical Practice Confidence Index Rises in 2012
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Post Your Comments:
(Date:11/24/2015)... NEW YORK , November 24, 2015 ... in a European healthcare ... in which the companies will work closely together in identifying ... of unmet medical need. The collaboration is underpinned by a ... LSP fund. This is the first investment by Bristol-Myers Squibb ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
(Date:11/23/2015)... Columbia, Md. (PRWEB) , ... November 23, 2015 ... ... R&D 100 award for the development of its Nexera UC Unified Chromatography system. ... the 100 most technically significant new products of the year in the analytical ...
(Date:11/23/2015)... PISCATAWAY, New Jersey , November 23, ... Centre (CCDC) announces the launch of the ... and the CSD-System, now complemented by three powerful ... support the discovery of new molecules, CSD-Materials for ... complete set of the CCDC,s applications incorporating CSD-Discovery ...
Breaking Biology Technology:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):